Organon And Co (OGN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Organon And Co's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Organon And Co's ROI in the second quarter of 2026?
Organon And Co recorded a cumulative net loss of $-5 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -0.05%.
Within the Healthcare sector 10 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1643 to 2417.
In a significant development within the pharmaceutical industry, the European Commission recently granted marketing authorization for two biosimilars, BILDYOS and BILPREVDA, both of which are versions of the established drug Denosumab. Developed by Henlius Biotech, based in Shanghai, and Organon, headquartered in Jersey City, these biosimilars serve as alternatives to Prolia and Xgeva, which are also Denosumab products used primarily for treating osteoporosis and preventing skeletal-related events in patients with bone metastases.The approval of BILDYOS and BILPREVDA holds great importance as it allows the companies to enter a competitive market for biosimilars, which are becoming increasingly essential in broadening access to advanced therapies while potentially lowering healthcare costs. The European Commission s endorsement encompasses all indications associated with the reference products, signaling confidence in the efficacy and safety profiles demonstrated by these biosimilars.
In a significant development that has garnered considerable attention in the pharmaceutical and investment communities, Organon and Co. (NYSE: OGN), a renowned healthcare company, faces a class action lawsuit amid financial turbulence in the first quarter of 2025. The legal proceedings have been initiated by Bronstein, Gewirtz and Grossman, LLC, a nationally acclaimed law firm known for its rigorous advocacy on behalf of investors. The suit is a result of substantial losses incurred by the investors of Organon and Co. highlighting a tumultuous period for the company as it navigates a challenging economic landscape.This legal battle coincides with a notable downturn in Organon and Co. s financial health, as evidenced by the recently reported results for the first quarter of 2025. The company experienced a striking revenue decline of 6.72% year-on-year, a figure that starkly contrasts with a relative revenue decrease of 2.82% witnessed by its peers in the same sector. Despite this, Organon and Co. managed to maintain a higher net margin of 5.75% compared to its competitors, suggesting a focus on operational efficiency amidst revenue pressures.
Shanghai Henlius Biotech, Inc. a leading biotechnology company, in collaboration with Organon, a global healthcare company focusing on women’s health, recently announced a significant milestone in the field of oncology treatment options. The Phase 3 clinical trial of the investigational biosimilar Perjeta (pertuzumab), known as HLX11, has successfully met its primary endpoint. This development marks a crucial step towards introducing more affordable and accessible biosimilar options to the market, potentially offering substantial benefits to patients requiring monoclonal antibody therapies.In 2022, Shanghai Henlius Biotech entered into a license and supply agreement with Organon, whereby Organon acquired exclusive global commercialization rights for two of Henlius s biosimilar candidates, including HLX11. The partnership aligns with both companies’ strategic s to enhance the availability of high-quality biosimilars, thereby reducing healthcare costs and increasing patient access to essential medicines.
Breaking New Ground in HER2-Positive Breast Cancer Treatment: Henlius HLX11 Competes with Perjeta In the ever-evolving landscape of oncology, the quest for innovative therapeutic options continues to be driven by the challenges faced in treating various forms of cancer, such as HER2-positive breast cancer. Shanghai Henlius Biotech, Inc. (2696.HK), has emerged as a significant player in this realm, particularly with its monoclonal antibody HLX11, which is under rigorous development to provide a robust alternative to Roche’s well-established treatment, Perjeta (pertuzumab).Perjeta is widely recognized for its critical role in the treatment regimen for HER2-positive breast cancer. It is predominantly used in combination with other agents to enhance therapeutic efficacy. The emergence of HLX11 represents an intriguing shift in competitive dynamics, as Henlius seeks to establish HLX11 as a viable, possibly more affordable, alternative to Perjeta. The Phase III clinical trial of HLX11, designated as HLX11-III, aims to evaluate its safety and efficacy against Perjeta, setting the stage for a potential breakthrough in treatment modalities. This pivotal trial, initiated in collaboration with Organon (NYSE: OGN), highlights the strategic partnership aimed at addressing the unmet clinical needs in the treatment of this aggressive cancer variant. The clinical trial design, denoted under study number CT05346224, focuses on specific endpoints including the response rate (ORR) and progression-free survival (PFS), measured through various assessment criteria such as IRC (independent review committee) and tpCR (total pathological complete response). Manifold results, including bpCR (bona fide pathological complete response), are anticipated to provide comprehensive insights into HLX11 s therapeutic profile relative to its rival.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
